NEW YORK, Feb 26: Michael Weitz was out of options. The Californian had endured chemotherapy, radiation and surgery but his lung cancer still spread to his bones and brain. With time running out, the emergency room physician entered a Phase I study – the earliest stage of human testing for a new medicine – of crizotinib. The drug works for about 4 percent of advanced lung cancer patients with a mutated form of a protein called ALK. (agencies)
Trending Now
E-Paper
Follow our WhatsApp channel